Latest News and Press Releases

Want to stay updated on the latest news?

Sign into Reader Account Create Reader Account

March 21, 2023 03:30 ET | Source: Selecta Biosciences, Inc.; Sobi

Phase 3 DISSOLVE Program of SEL-212 in Chronic Refractory Gout Meets Primary Endpoint

--Response rate of 56% in patients treated monthly with high dose SEL-212 in DISSOLVE I and 47% in DISSOLVE II--In patients 50 years and older, response rate with high dose SEL-212 was 65% in DISSOLVE...
March 02, 2023 07:30 ET | Source: Selecta Biosciences, Inc.

Selecta Biosciences Reports Fourth Quarter and Full Year 2022 Financial Results and Provides Business Update

- Topline data for Phase 3 DISSOLVE I & II clinical trials of SEL-212 in chronic refractory gout remains on track for Q1 2023 - - Continue to enroll patients in ReiMMAgine, the Phase 1/2 clinical...
February 23, 2023 08:00 ET | Source: Selecta Biosciences, Inc.

Selecta Biosciences to Host Conference Call and Webcast to Discuss Fourth Quarter and Full-Year 2022 Financial Results and Provide Business Update

WATERTOWN, Mass., Feb. 23, 2023 (GLOBE NEWSWIRE) -- Selecta Biosciences, Inc. (NASDAQ: SELB), a biotechnology company leveraging its clinically validated ImmTOR™ platform to develop tolerogenic...
February 07, 2023 08:00 ET | Source: Selecta Biosciences, Inc.

Selecta Biosciences to Participate at the SVB Securities Global Biopharma Conference

WATERTOWN, Mass., Feb. 07, 2023 (GLOBE NEWSWIRE) -- Selecta Biosciences, Inc. (NASDAQ: SELB), a biotechnology company leveraging its clinically validated ImmTOR™ platform to develop tolerogenic...
January 09, 2023 08:00 ET | Source: Selecta Biosciences, Inc.

Selecta Biosciences Provides Business Update and Outlook for 2023

- Expected topline data for Phase 3 DISSOLVE I & II programs of SEL-212 in chronic refractory gout in Q1 2023 - - To receive $10 million upfront for the execution of a license agreement for Xork,...
December 14, 2022 08:00 ET | Source: Selecta Biosciences, Inc.

Selecta Biosciences Announces Next Generation IgA Protease Clinical Candidate Selection for IgA Nephropathy Program

– IgA protease candidate in combination with ImmTOR further enhances pipeline – – Novel mechanism of action of IgA protease has the potential to address the underlying kidney pathophysiology of IgA...
November 28, 2022 08:00 ET | Source: Selecta Biosciences, Inc.

Selecta Biosciences Announces Appointment of Blaine Davis as Chief Financial Officer

WATERTOWN, Mass., Nov. 28, 2022 (GLOBE NEWSWIRE) -- Selecta Biosciences, Inc. (NASDAQ: SELB), a biotechnology company leveraging its clinically validated ImmTOR™ platform to develop tolerogenic...
November 07, 2022 08:00 ET | Source: Selecta Biosciences, Inc.

Selecta Biosciences to Participate at the Guggenheim Healthcare Talks | 4th Annual Immunology & Neurology Day

WATERTOWN, Mass., Nov. 07, 2022 (GLOBE NEWSWIRE) -- Selecta Biosciences, Inc. (NASDAQ: SELB), a biotechnology company pioneering precision immune tolerance with its clinically validated ImmTOR®...
November 03, 2022 08:00 ET | Source: Selecta Biosciences, Inc.

Selecta Biosciences Reports Third Quarter 2022 Financial Results and Provides Business Update

– DISSOLVE I & II studies of SEL-212 in Chronic Refractory Gout remain on track for joint topline data readout in Q1 2023 – – SEL-302, Selecta’s wholly owned gene therapy in combination with...
October 27, 2022 08:00 ET | Source: Selecta Biosciences, Inc.

Selecta Biosciences to Host Conference Call and Webcast to Discuss Third Quarter 2022 Financial Results and Provide Business Update

WATERTOWN, Mass., Oct. 27, 2022 (GLOBE NEWSWIRE) -- Selecta Biosciences, Inc. (NASDAQ: SELB), a biotechnology company pioneering precision immune tolerance with its clinically validated ImmTOR®...